Many local pharma companies in Turkey have been launching capital investments in new production facilities for biologics and biosimilars in the hope of attracting new foreign partners and have already met with some success, but a number of obstacles remain.
Boehringer Ingelheim’s head of BioXcellence, its contract manufacturing business, talks to Scrip about best practice when forming a long-term relationship with an outsourcing services provider.
German group Merck has inaugurated a major new pharmaceutical plant and announced a further investment in China, where it sees opportunities in essential drugs amid rising demand as the country broadens its basic healthcare coverage and its population ages.
Chapter sponsored by:
You must sign in to use this functionality.
Please Sign In
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with active subscriptions will be able to access the full article. All other readers will be directed to the abstract and may purchase the article.